The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only [...]
In yesterday’s post, Provenge, Its Future & A Clinical Trail Alternative for Men with Hormone Dependent Prostate Cancer, I said that I attempted to get into a vaccine trial, but was rejected because I have a history of an autoimmune disease and I have had evidence of some lymph node involvement (stage D1). I want [...]
I have received a number of e-mails from men who are both frustrated that Provenge is not yet approved and who are frustrated that even when approved they will not qualify to get the treatment. I understand the frustration and feel the same way. The first question is will the FDA approve Provenge? Only time [...]
Clinical Trials That Exclude Gay and Lesbian Patients By Darryl (published on Malecare’s blog at: prostatecancerblog.org The March 18, 2010 issue of *New England Journal of Medicine* (Volume 362, #11, March 18) includes a study: “Clinical Trials That Explicitly Exclude Gay and Lesbian Patients.” […]
I often try and steer a little clear of the most controversial of issues effecting those of us with prostate cancer, but despite personal opinions, the recent health care reform passed in the United States requires discussion. The reform legislation, besides representing the most sweeping social policy change in the U.S. in decades will have [...]